Navigation Links
New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen
Date:11/13/2007

Fast-dissolve method uses the latest advancement in aspirin delivery

technology.

CLEVELAND, Nov. 13 /PRNewswire/ -- Improvita Health Products, Inc. has rolled out Fasprin(R), a patented, 81 milligram aspirin tablet that dissolves rapidly in the mouth instead of in the stomach, offering an effective, simplified solution for the millions of Americans who maintain a daily aspirin routine and worry about gastrointestinal bleeding or swallowing pills.

A daily low-dose aspirin therapy is commonly prescribed to adults to prevent heart attack and stroke and help improve blood flow to the heart. Small daily doses of aspirin have proven to be effective in reducing the chances of mini-strokes (in which clogged blood vessels prevent sufficient oxygen from reaching the brain). Aspirin is also used to reduce the risk of heart attack in people with clogged coronary arteries, and in those who've already had an attack.

With its great-tasting "citrus burst" flavor, Fasprin is ideal for patients on a daily heart health aspirin regimen and is sugar free for diabetics.

Fasprin's patented, no-swallow aspirin delivery method reduces irritation to the gastrointestinal tract by quickly dissolving in the mouth, which allows the aspirin to enter the blood stream in just three to five minutes, or up to ten times faster than conventional aspirin that typically is absorbed through the stomach.

Tom Klamet, president of Improvita Health Products, Inc., noted that the low-dose aspirin tablet uses the latest technology for delivering the required dosage to the blood stream. "Fasprin was developed by a physician who saw the many benefits of an aspirin that could be administered quickly and effortlessly," he commented. "A daily aspirin regimen can fast become a chore, especially for older adults who have a hard time swallowing a full tablet. Fasprin's ability to dissolve on the tongue ensures 100 percent bioavailability, or the de
'/>"/>

SOURCE Improvita Health Products, Inc.
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 Today marks the launch ... Itinerary Builder. , The redesigned and enhanced Itinerary ... vacation itineraries on their computer or mobile device that ... interactive tool allows users to fill in their date ... and select their choice of vacation packages, accommodations, restaurants, ...
(Date:5/24/2013)... Bridal Buy , a leading wedding ... 2013 bridesmaid dresses are available in its wedding ... featured as fine fabrics, elegant beading, and exquisite embroidery. ... and an eye for detailed designs. However, our lace ... life from patterns and the hands of dressmakers,” said, ...
(Date:5/24/2013)... The leading retail brand Short Dresses has recently ... . Now that is quite unbelievable, especially in view of ... since its origin. The retailer has already revealed its wider ... discount offer will be an added bonanza for the frequent ... announce that Short Dresses is to offer different levels of ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 ... the Cellulite Whisperer line, with a ... for Summer Sale" includes two proprietary products, the ... Whisperer® Lotion . , Purchasers receive a report ... , "The Gel has a wonderful grapefruit scent," ...
(Date:5/23/2013)... Whether working in an urban setting ... enforcement need an added layer of protection at night. ... VISER , is an effective portable, rugged, rapidly deployable ... increase border and perimeter security. , Today, ARA announces ... tripled over the past three years, with most systems ...
Breaking Medicine News(10 mins):Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3
... Million Americans Have Parkinson,s Disease, Roughly ... ... 21 Accolade, a Texas-based home,healthcare and hospice provider, observes ... Parkinson,s disease.,Accolade,s innovative short-term program enables people living with the,disease ...
... proved more beneficial than individual grief counseling, study finds ... experience the unexpected death of a parent after a ... finding that has major implications for helping children deal ... "Often children who have lost a parent are given ...
... than 6 millimeters in diameter appear more likely to ... in the April issue of Archives of Dermatology, one ... diameter guidelines currently used by dermatologists to screen for ... method to screen for melanoma, according to background information ...
... Decisions on Bottom Line Return at 3rd Annual ... Pharmaceutical Market Research Summit, NEW ... the pharmaceutical analytics company Eularis, will be,delivering a presentation on ... Research and Decisions on Bottom Line Return., ...
... of West Nile Virus and Other Diseases, SACRAMENTO, ... in hand. Coinciding with the launch of mosquito season, ... to April 25,2008 West Nile Virus and Mosquito and ... a mosquito-borne disease that can result in,debilitating cases of ...
... suggests , , MONDAY, April 21 (HealthDay News) -- The ... disease than women appear during the adolescent years, according a ... , "This is not what we would have predicted," said ... the University of Minnesota Children,s Hospital, and lead author of ...
Cached Medicine News:Health News:April is National Parkinson's Disease Awareness Month 2Health News:April is National Parkinson's Disease Awareness Month 3Health News:Treating PTSD Helps Kids Deal With Loss 2Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eularis to Address Making the Right Research Decision for ROI 2Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2Health News:Heart Disease Risks Hit Boys in Teens 2
(Date:5/24/2013)... 24, 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the ... announced today that Dr. Robert Grieve , ... Jason Napolitano , executive vice president and chief financial ... which is being held May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4
... Campath May Lead to Overall Survival in Patients with Poor ... FRANCISCO, Dec. 9 Bayer HealthCare Pharmaceuticals Inc. today announced ... showed activity in high-risk chronic lymphocytic leukemia (CLL) patients who ... 50th Annual Meeting of the American Society of Hematology in ...
... 8 Millennium: The Takeda Oncology Company today ... of patients from the large, international Phase III ... with previously untreated multiple myeloma given VELCADE, melphalan ... efficacy in all patient sub-groups, including those with ...
Cached Medicine Technology:Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 2Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 3Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 4Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 5Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 6Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 7Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 8Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 9Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL 10Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 2Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 3Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 4Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 5Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma 6
Super High Density, multi-frequency, phased array burr hole transducer. Excellent for taking biopsy samples and shunt placements....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
Medicine Products: